Please assess the completion status of the following clinical trial:

Trial Title: Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Require treatment for MF and classified at least as intermediate risk level 1 defined by the International Working Group.~* Platelet count \< 100x10 \^9/L at screening or at Study Day 1.~Exclusion Criteria:~* Received platelet transfusion within 14 days prior to Screening evaluations.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stratum -1 (Type: EXPERIMENTAL): Participants with baseline Platelet counts of 75-99 x10\^9/L
- Stratum -2 (Type: EXPERIMENTAL): Participants with baseline Platelet counts of 50-74 x10\^9/L

Based on this trial design, predict the completion outcome and termination type (if applicable).